A new review addresses the mysteries behind “good” HDL cholesterol and why boosting its levels does not necessarily provide protection from cardiovascular risk for patients. It appears that augmenting the function of HDL cholesterol, rather than its concentration, is key.
A new review addresses the mysteries behind “good” HDL cholesterol and why boosting its levels does not necessarily provide protection from cardiovascular risk for patients. It appears that augmenting the function of HDL cholesterol, rather than its concentration, is key.
The review details the manner in which tissue and systemic inflammation affects the metabolism of HDL cholesterol via several pathways, pointing to ways to improve its production and function.
“Our own clinical studies as well as in vitro and animal studies performed by other groups have demonstrated the significance of adipose, or fat, tissue for optimal HDL cholesterol metabolism and function. Currently, it is accepted that adipose tissue inflammation is one of the hallmarks of systemic inflammation, thus, it is our hypothesis that addressing adipose tissue–associated systemic inflammation will support the atheroprotective role of HDL,” said Dr. Demidmaa Tuvdendorj, senior author of the British Journal of Pharmacology article.
Additional Information
Link to study: http://doi.wiley.com/10.1111/bph.13743
About Journal
The British Journal of Pharmacology is a broad-based journal giving leading international coverage of all aspects of experimental pharmacology. It publishes high quality original research and authoritative reviews. Each year a range of themed issues are published and a must-read supplement, the Concise Guide to Pharmacology is published biennially.
Penny Smith
+44 (0) 1243 770448
sciencenewsroom@wiley.com